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Abstract
Background: Cryptococcus neoformans (Cn) is an important opportunistic pathogen in the immunocompromised
people, including AIDS patients, which leads to fatal cryptococcal meningitis with high mortality rate. Previous
researches have shown that HIV-1 gp41-I90 ectodomain can enhance Cn adhesion to and invasion of brain
microvascular endothelial cell (BMEC), which constitutes the blood brain barrier (BBB). However, little is known
about the role of HIV-1 gp41-I90 in the monocyte transmigration across Cn-infected BBB. In the present study,
we provide evidence that HIV-1 gp41-I90 and Cn synergistically enhance monocytes transmigration across the
BBB in vitro and in vivo. The underlying mechanisms for this phenomenon require further study.
Methods: In this study, the enhancing role of HIV-1 gp41-I90 in monocyte transmigration across Cn-infected
BBB was demonstrated by performed transmigration assays in vitro and in vivo.
Results: Our results showed that the transmigration rate of monocytes are positively associated with Cn and/or
HIV-1 gp41-I90, the co-exposure (HIV-1 gp41-I90 + Cn) group showed a higher THP-1 transmigration rate (P < 0.01).
Using CD44 knock-down HBMEC or CD44 inhibitor Bikunin in the assay, the facilitation of transmigration rates of
monocyte enhanced by HIV-1 gp41-I90 was significantly suppressed. Western blotting analysis and biotin/avidin
enzyme-linked immunosorbent assays (BA-ELISAs) showed that Cn and HIV-1 gp41-I90 could increase the expression of
CD44 and ICAM-1 on the HBMEC. Moreover, Cn and/or HIV-1 gp41-I90 could also induce CD44 redistribution to the
membrane lipid rafts. By establishing the mouse cryptococcal meningitis model, we found that HIV-1 gp41-I90 and Cn
could synergistically enhance the monocytes transmigration, increase the BBB permeability and injury in vivo.
Conclusions: Collectively, our findings suggested that HIV-1 gp41-I90 ectodomain can enhance the transmigration of
THP-1 through Cn-infected BBB, which may be mediated by CD44. This novel study enlightens the future prospects to
elaborate the inflammatory responses induced by HIV-1 gp41-I90 ectodomain and to effectively eliminate the
opportunistic infections in AIDS patients.
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Background
Cryptococcus neoformans (Cn) is an important patho-
genic fungus with capsule and causes severe meningitis
and disseminated infections, especially in patients with
defective cellular immunity, such as AIDS patients [1, 2].
Cryptococcosis is the most common opportunistic fun-
gal infection and one of the major causes of death in
AIDS patients (mortality rate ~ 30 %) [3, 4]. Despite
major advances in the treatment of HIV-1 infection with
Highly Active Antiretroviral Therapy (HAART), crypto-
coccosis remains prevalent even in developed countries
[5–9]. Cn infects mainly through the respiratory tract,
spreads from the pulmonary circulation to the brain tis-
sues, resulting in meningitis [10, 11]. The pathogenesis
of cryptococcal meningitis (CM) is still largely unknown,
while it is well known that crossing the BBB is the pivotal
step leading to the development of meningitis. The dam-
age of the BBB is generally induced by the interactions be-
tween pathogens and brain microvascular endothelial cells
(BMECs), which leads to edema and increased permeabil-
ity, and subsequently facilitate more interactions between
the immune cells and BMECs [12]. Previous research had
shown that Cn is able to cause considerable morpho-
logical changes and actin reorganization in HBMEC [1].
Many signaling molecules, including CD44, caveolin-1,
PKCα, endocytic kinase DYRK3, in lipid rafts have been
characterized and shown to play an important role during
the Cn internalization [2, 13–16].
Cryptococcosis is one of the most fatal co-morbidity
factors of AIDS. The interrelationship between HIV-1
and Cn is intriguing and intricate, as both pathogens
cause severe neuropathological complications. The de-
tails of how HIV-1 virotoxins, including gp120 and
gp41, enhance Cn invasion of the BBB are still largely
unknown. Our recent study has shown that HIV-1-
gp41-I90 has a remarkable effect in promoting the adhe-
sion and invasion of Cn [17]. Through construction of a
recombinant protein, HIV-1 gp41-I90, which is the ecto-
domain of gp41 (amino acid residues 579–611), we have
shown that HIV-1 gp41-I90 ectodomain could activate
many molecular events including up-regulation of
ICAM-1 on the HBMEC, redistribution of CD44 and β-
actin on the lipid rafts and induction of membrane ruf-
fling on the surface of HBMEC. These events could en-
hance brain invasion by Cn and eventually can lead to
severe HIV-1-associated CM [17, 18]. CD44 is a cell-
surface glycoprotein involved in cell–cell interactions,
cell adhesion and migration, which is widely distributed
in a variety of endothelial cells, including HBMEC [19].
The interaction between hyaluronic acid (HA) on the
Cn and its receptor CD44 on the surface of HBMEC is
the initial step in cryptococcal brain invasion [13]. The
role played by CD44/HA in the interaction between
BMECs and leukocytes and the exudation of leukocyte is
previously characterized [13]. CD44 has also been pro-
posed to play an important role in Cn infection-induced
adhesion and transmigration activities of leukocyte. It is
reasonable to speculate that CD44 could also be import-
ant for HIV-1 gp41-I90 ectodomain mediated brain in-
vasion of Cn.
Delineating the mechanism of Cn transmigration across
the BBB is essential to explore the potential of HIV-1 in
enhancing the brain invasion by Cn. Many research
groups have suggested three possible routes of Cn trans-
migration across the BBB: (1) Trans-cellular passage
through endothelial cells by a specific ligand-receptor
interaction [1, 20], this mode of invasion has been ob-
served for Escherichia coli [21–23], group B Streptococcus
[24], Listeria monocytogenes [25], Neisseria meningitides
[26] and the fungal pathogen Candida albicans [27]; (2)
Paracellular penetration after mechanical or biochemical
disruption of the BBB [1, 28, 29], just like the protozoan
Trypanosomasp [30, 31]; (3)“Trojan horse” method, in
which the infected immune cells, such as monocytes carry
the pathogen through the BBB, a method of infection by
HIV-1 and simian immunodeficiency virus [32–34]. The
existence of a Trojan horse method of crossing the BBB
by Cn has been proved in a study by Caroline Charlier et
al. [35]. Through infecting bone marrow-derived mono-
cytes (BMDM) with Cn in vitro, the authors showed that
fungal loads in brain of mice treated with Cn-infected
BMDM were much higher than the control group. Accu-
mulating evidence shows that Cn can use multiple means
of transmigration and disruption of the BBB.
Previous research had shown that HIV-1 infection is
able to increase the monocyte capacity to migrate across
the BBB [36]. As existence of a Trojan horse method of
crossing the BBB by Cn, it is reasonable to speculate that
HIV-1 enhanced transmigration activity of monocytes
might be responsible for severe brain disorder caused by
Cn. In present study, through performing transmigration
assays, we found that Cn and HIV-1 gp41-I90 could syn-
ergistically enhance monocytes transmigration across the
BBB. Our findings provide a new idea for understanding
the interrelationship between HIV-1 and Cn during the
pathogenic progress of HIV-1-associated CM.
Methods
Chemicals and reagent
Evans blue (EB), L-(−)-Fucose, biotinylation kit and Caveo-
lae/Rafts Isolation kit were purchased from Sigma-Aldrich
(St. Louis, MO). Dynabeads M-450 Tosylactivated was pur-
chased from Invitrogen (Carlsbad, CA). Ulex europaeus I
(UEA I) lectin and mounting medium with DAPI were
purchased from Vector (Buringame, CA). The HIV-1
gp41-I90 ectodomain peptide (gp41-I90) was prepared as
previously described [37]. Recombinant HIV-1 Tat clade B
protein and HIV-1 p24 recombinant were purchased from
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Prospec (Rehovort, Israel). All primary antibodies (Ab)
were purchased from the commercial sources: a rabbit
anti-MSFD2 Ab (sc-135305), a rabbit anti-CD44 Ab, a rat
anti-Ly6C Ab and a rabbit anti-ICAM-1 Ab (Abcam,
USA), a PE-conjugated anti-CD146 Ab (12-1469-41) and a
PE-conjugated rat anti-mouse Ly6C Ab from eBiosciences
(San Diego, CA, USA). The rest chemicals were obtained
from Ding Guo Chang Sheng Company, Beijing, China.
Fungi strains, cell lines and cultures
Cn wild strains B-4500FO2 was a generous gift from A
Jong (University of Southern California, Los Angeles, USA).
Yeast cells were grown aerobically at 30 °C in 1 % yeast ex-
tract, 2 % peptone and 2 % dextrose (YPD broth). Cells
were harvested at early log phase, washed with phosphate-
buffered saline (PBS) and resuspended. The yeast cell
number was determined by direct counting from a
hemocytometer [17]. Heat-inactivated Cn (H-Cn) was ob-
tained by heating the microorganisms three times at 121 °C
for 15 min [38]. Only batches that showed no re-growth in
YPD broth were employed. HBMEC were isolated and cul-
tured as described previously [39–41], which were grown
in RPMI 1640 medium supplemented with 10 % heat-
inactivated fetal bovine serum, 10 % Nu-serum, 2 mM glu-
tamine, 1 mM sodium pyruvate, nonessential amino acids,
vitamins, penicillin G (50 μg/ml) and streptomycin
(100 μg/ml) at 37 °C in 5 % CO2. Cells were detached by
trypsin-EDTA and subcultured on collagen-coated Trans-
well (3 μm pore size, 6.5-mm diameter) (BD Biosciences,
San Jose, CA, USA) from T-25 flasks when ~70 %–80 %
confluent. HBMEC monolayers on Transwell filters were
monitored by measuring trans-endothelial electrical resist-
ance (TEER) changes across the endothelial cell monolayer
using an End Ohm epithelial voltohmeter (World Precision
Instruments, Sarasota, FL, USA) [1, 27]. The cells are
positive for factor VIII and fluorescently labeled acety-
lated low-density lipoprotein (Dil-AcLDL) uptake, dem-
onstrating their endothelial origin and also express
gamma glutamyl transpeptidase (GGT) and carbonic
anhydrase (CA) IV, indicating their brain origin [42].
HBMEC are polarized and exhibit an average TEER
value of 250–300Ω/cm2 [1]. The cells also exhibit the
typical characteristics for brain endothelial cells ex-
pressing tight junctions and maintaining apical-to-basal
polarity. THP-1 cells were purchased from the cell bank
of Chinese Academy of Sciences and grown in RPMI
1640 medium supplemented with 10 % heat-inactivated
fetal bovine serum, penicillin G (50 μg/ml) and strepto-
mycin (100 μg/ml) at 37 °C in 5 % CO2.
Mice
The C57BL/6 background mice (6 weeks of age) were
brought from Animal Experimental Center of Southern
Medical University (Guangzhou, China) and kept in the
animal facility. They were raised in plastic cages and given
food and water ad libitum. All experiments were approved
by the ethics committee of Southern Medical University.
CRISPR/Cas9-Mediated knockdown-CD44
The CRISPR-Cas9 system was used in our study to me-
diate down-regulated expression of CD44 in HBMEC.
Human CD44 cDNA sequence was obtained from Gen
Bank (NM_000610) and two pairs of single guide RNA
(sgRNA) sequences (named CD44-1 and CD44-2, as
below) were designed online (http://www.e-crisp.org/E-
CRISP/designcrispr.html). The underlined sequences tar-
geted the CD44 gene, and the bold italic letters indicate
the BsmBI site. A 20 bp scrambled sequence (see below)
was defined as a scramble control which was marked










These sequences were annealed in 10 × T4 Ligation Buf-
fer (NEB) withT4 PNK (NEB M0201S) by incubating oligo-
nucleotides for 30 min at 37 °C, 5 min at 95 °C and
ramping down to 25 °C at 5 °C/min, followed by slow cool-
ing to 4 °C. The annealed DNA fragments were ligated into
BsmBI sites of lentiCRISPRv2 (provided by Bao Zhang,
Southern Medical University) to generate lentiCRISPRv2-
CD44-1, lentiCRISPRv2-CD44-2 and lentiCRISPRv2-SC
plasmids, respectively. These plasmids were transfected
into 293 T cells with lentiviral packaging vectors pCMV-
dR8.2 dvpr and pCMV-VSV-G (both provided by Bao
Zhang, Southern Medical University) using lipofectamine
2000. Viruses were collected from the media 48 h post-
transfection. HBMEC grown on 24 well plates were in-
fected with collected viruses for 24 h in the presence of
polybrene (Santa Cruz). Stably transfected clones were
picked and maintained in medium containing 2 μg/ml
puromycin for additional studies. Expression level of CD44
in stable cell line was analyzed by western blotting using
anti-CD44 monoclonal antibodies. We assigned the stable
cell line as KD-CD44 HBMEC in our study.
THP-1 adhesion assay
THP-1 adhesion assays were performed as described by
Che et al. [43]. Briefly, confluent HBMEC monolayers on
24-well plates were stimulated with different concentrations
of Cn (105-2 × 107 CFU/ml) or gp41-I90 (0.02–20 μM) for
6 h. For the time-course study, confluent HBMEC mono-
layers were stimulated at different time intervals (0–24 h)
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with a single dose of Cn (5 × 106 CFU/ml) or HIV-1 gp41-
I90 (2 μM). After the incubation, monolayers were washed
with PBS for four times. Each well was added with 1 × 106
THP-1 and incubated with 90 min at 37 °C. Then, cells
were washed for 5 times and fixed with 4 % paraformalde-
hyde in PBS. Assays were performed in triplicate wells.
Fifteen microscope fields were randomly selected from
three wells for each treatment to count the number of ad-
herent monocytes and the data were analyzed using analysis
of variance (ANOVA).
THP-1 transmigration assay
THP-1 transmigration assays were performed as described
previously [44, 45] with modification. HBMECs or KD-
CD44 HBMECs were cultured in trans-well filters (3 μm
pore size, 6 mm diameter, Millipore). In order to exclude
the possibility that the monocytes migration elicited was
due to destruction of HBMEC, the integrity of the mono-
layer was inspected by TEER and microscopy before the
start of the assay. For HBMEC stimulation, different doses
of Cn or HIV-1 gp41-I90 were added to the upper cham-
bers with 0.8 ml EM (EM; containing 49 % M199, 49 %
Ham’s F12, 1 mM sodium pyruvate and 2 mM L-glutam-
ine) for 6 h. For the time-course study, HBMEC were
stimulated at different time intervals (0–24 h) with a sin-
gle dose of Cn (5 × 106 CFU/ml) Cn or HIV-1 gp41-I90
(2 μM). After stimulation, THP-1 (1 × 106 cells in 0.2 ml
of EM) were added to the upper chamber and allowed to
migrate over for 4 h (Dose response and kinetic assays
were performed in advance to determine the optimized
concentration and migration duration). At the end of the
incubation, migrated THP-1 cells were collected from the
lower chamber and counted in a blinded-fashion using a
hemacytometer [43]. Final results of THP-1 transmigra-
tion were expressed as the percentage of THP-1 across
the BMEC monolayers. For Bikunin treatment, BMEC
were incubated with Bikunin (Gen-Script Corp., catalog
no. 300233) in both upper and lower chambers for 1 h be-
fore stimulation [16]. The pre-treating time of bikunin
was determined according to kinetic assays. The Bikunin
was present throughout the monocytes transmigration ex-
periment until the end.
Assays of surface expression of CD44 and ICAM-1
As ICAM-1 and CD44 play a role in the leukocyte trans-
migration process during inflammatory, we next per-
formed BA-ELISAs to measured the expression of CD44
and ICAM-1 on HBMEC. Before the assays, ICAM-1 and
CD44 antibody were biotinylated with biotin using a bio-
tinylation kit as described by the manufacturer. The
methods for ELISAs were similar to those described previ-
ously [43]. HBMEC monolayers which grown on Trans-
well were treated with Cn (5 × 106 CFU/ml) and HIV-1
gp41-I90 (2 μM) alone or joint use of them and incubated
for 6 h. Treated monolayers were washed three times with
PBS, fixed with 4 % paraformaldehyde and blocked for
30 min with PBS containing 5 % BSA. Biotin conjugated
ICAM-1 antibody or CD44 antibody were added immedi-
ately after the blocking step. Incubation was carried out
for 1 h at 37 °C. Cells were washed five times with PBS
added 1 % BSA and incubated with peroxidase-conjugated
avidin for 45 min at 37 °C. After the avidin incubation,
cells were washed five times and liquid TMB substrate
was added. The liquid was transferred to an ELISA plate
after 15 min. Equal volume stop solution was added, and
optical density at 450 nm was read. For each ELISA, an
isotype-matched control antibody was used in place of the
primary antibody in three wells, and this background was
subtracted from the signal.
Preparation of membrane lipid rafts from HBMECs
Lipid rafts were extracted using Caveolae/Rafts Isolation
kit as described previously [13]. For each sample,
HBMECs were grown in a 6 well plates for 2 days. On the
day of the experiment, the cells were individually incu-
bated with either PBS (control), or 2 μM HIV-1 gp41-I90,
or 5 × 106 CFU/ml Cn or 5 × 106 CFU/ml Cn + 2 μM
HIV-1 gp41-I90 individually for 6 h in the experimental
medium. After incubation, the cells were washed with
PBS three times, scraped in PBS and spun down at 750 g
at 4 °C. Cell pellets were lysed in 200 μl of TN solution
[25 mM Tris/HCl (pH 7.5), 1 mM DTT (dithiothreitol), a
cocktail of protease inhibitors, 10 % sucrose and 1 % Tri-
ton X-100] on ice, and incubated for 30 min on ice. Sam-
ples were mixed with 1.16 ml of ice-cold OptiPrepTM,
transferred into SW40 centrifuge tubes and overlaid with
2 ml each of 30, 30, 25, 20 and 0 % OptiPrepTM in TN
buffer. The gradients were spun at 35000 r.p.m. in an
SW40 rotor for 5 h at 4 °C. Nine fractions were col-
lected from the top to the bottom of centrifuge tubes.
For western blotting, equal amounts of proteins from
each fraction were used. Rabbit anti-CD44 Ab (Abcam,
1:5000 dilution) and anti-rabbit-HRP conjugate (1:500
dilution) were used in these experiments.
Western blotting analysis
To assess Cn or HIV-1 gp41-I90 induced expression of
CD44 and ICAM-1 on HBMEC, monolayers was sub-
jected to individual treatment with PBS, 5 × 106 CFU/ml
Cn, 2 μM HIV-1 gp41-I90, 5 × 106 CFU/ml Cn + 2 μM
HIV-1 gp41-I90 or 0, 0.2, 2 and 20 μM HIV-1 gp41-I90
respectively for 6 h at 37 °C in 5 % CO2. After incubation,
the cells were collected and lysed on ice in lysis buffer
[1 × PBS, 1 % NP40, 0.1 % sodium dodecyl sulphate,
5 mM ethylenediaminetetraacetic acid (EDTA), 0.5 % so-
dium deoxycholate, 1 mM sodium orthovanadate] with
protease inhibitors. The protein concentration was mea-
sured using the Bradford protein assay (Beyotime Institute
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of Biotechnology, Shanghai, China). Equal amounts of pro-
teins were separated electrophoretically and transferred
onto polyvinylidene difluoride membranes (Millipore). Each
membrane was probed with a rabbit anti-CD44 antibody
(1:5000) or rabbit anti-ICAM-1antibody (1:200). Expression
of protein was examined with a horseradish peroxidase-
conjugated anti-rabbit IgG and enhanced chemilumin-
escence (Pierce, Rockford, IL, USA). A goat polyclonal
anti-β-actin antibody (1:1500; Santa Cruz Biotechnol-
ogy) was used to confirm equal loading of proteins.
The intensity of the bands was scanned and analyzed
with Alpha Imager gel documentation system and ana-
lysis software.
Mouse cryptococcal meningitis model
All the animal experiments were performed strictly accord-
ing to the guidelines for animal care in Southern Medical
University (China). Our protocols were approved (Ap-
proval No. 2014A016) by the School of Public Health and
Tropical Medicine of Southern Medical University, which
obtained the permission for performing the research proto-
cols and all animal experiments conducted during the
present study from the ethics committee of Southern Med-
ical University. All surgery was performed under anesthesia
with ketamine and lidocaine, and all efforts were made to
minimize suffering. For study the role of HIV-1 gp41-I90
on Cn-caused monocyte recruitment into the CNS of mice,
mouse cryptococcal meningitis model was established as
described previously [17]. 6 weeks-old C57BL/6 mice (6
mice each group) were intravenously injected with 106 Cn
cells via the tail vein, with or without HIV-1 gp41-I90
(10 μg/g mouse weight). After 24 h injection, mice were
anaesthetized with ketamine and lidocaine, and blood sam-
ples were collected from heart puncture for isolation and
purification of mouse brain microvascular endothelial cells.
After perfusion from heart puncture with 20 ml PBS, the
skull was opened. CSF samples were collected by washing
the brain tissues with 100 μl of PBS, and then by washing
the cerebral ventricles and cranial cavity with another
100 μl of PBS. CSF samples containing more than 10 eryth-
rocytes per μl were discarded as contaminated samples. As
the expression level of CD14 is very low in mouse mono-
cytes, anti-Ly6C Ab was used to determine monocyte in
CSF [46]. Monocytes were stained with a PE-conjugated
rat anti-mouse Ly6C Ab (eBiosciences, CA, USA) and
counted under the fluorescence microscope.
Isolation and purification of mouse brain microvascular
endothelial cells
Recently, we have demonstrated that circulating BMECs
(cBMECs) can be used as potential novel cell-based
biomarkers for indexing of the BBB injury [47]. This
technology was used by us to explore whether HIV-1
gp41-I90 is able to increase Cn-associated BBB damages
in our study. Briefly, beads were prepared according to
the manufacturer’s instructions (Invitrogen) and resus-
pended in Hanks’ balanced salt solution (HBSS, Invitro-
gen Corp., Carlsbad, CA, USA) plus 5 % fetal calf
serum (HBSS + 5 %FCS) to a final concentration of 4 ×
l08 beads/ml. The cBMECs were prepared as described
previously [47, 48]. Endothelial cells from blood sam-
ples were isolated by absorption to Ulex-coated beads
[49] and detached from the beads by fucose. Detached
endothelial cells were adhered again to MFSD2a-coated
beads. To counting the cBMECs from blood samples,
cells adhered to MFSD2a-coated beads were labeled with
PE-conjugated CD146 antibody and transferred to glass
splices by cytospin for counting under a fluorescence
microscope. These endothelial cells were positive for
CD146 [47], demonstrating their endothelial origin, and
also expressed MFSD2a [50], indicating their brain origin.
Total cBMECs were identified based on their CD146
(endothelial cell marker)+/DAPI (nuclei)+phenotypes.
Histopathology and immunohistochemistry
Mouse brain tissue was fixed in 4 % phosphate-buffered
paraformaldehyde and was paraffin-embedded. Immuno-
histochemistry was performed on 5 μm paraffin tissue
sections. Mouse monocytes were identified with anti-
Ly6C (1:100; Abcam). To detect primary Abs, a goat
anti-rabbit antibody conjugated with horseradish perox-
idase was used with 50 mM Tris · HCl buffer (pH 7.4)
containing DAB and H2O2, and the sections were lightly
counterstained with hemotoxylin.
Statistical analysis
Data are shown in mean ± standard deviation and ana-
lyzed by one-way ANOVA tests. All statistical analysis
was carried out at 5 % level of significance and P value
less than 0.05 was considered to be significant. SPSS
software (version 13.0) was used for statistical analysis.
The synergistic enhancing effect on joint use of Cn and
HIV-1 gp41-I90 was analyzed using the CalcuSyn Soft-
ware (Biosoft).
Results
Effect of Cn and HIV-1 gp41-I90 on adhesion and
transmigration of THP-1
Recruitment of monocytes into CNS plays an important
role in the inflammatory response induced by fungal fac-
tors [51]. To determine the role of Cn and HIV-1 gp41-I90
on transmigration of monocytes, we first evaluated the ef-
fect of Cn and HIV-1 gp41-I90 on monocytes adhesion to
HBMEC at different yeast doses (106-2 × 107 CFU/ml) and
time intervals (0–24 h). Individually, as shown in Fig. 1a–d,
Cn and gp41-I90 not only could dose-dependently induce
adhesion of monocytes to HBMEC, but also it is time-
dependent. Next, we performed transmigration assays to
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test whether Cn and HIV-1 gp41-I90 could induce mono-
cytes transmigration across the BBB in vitro at a manner
similar to adhesion. As we expected, Cn and HIV-1 gp41-
I90 could also induce monocytes transmigration across the
BBB in vitro in a dose- and time-dependent manner
(Fig. 2a–d). In order to exclude the possibility that the in-
creased transendothelial migration by Cn or HIV-1 gp41-
I90 was due to disruption of the BBB, the integrity of the
monolayer was inspected by determining the TEER across
the monolayer. As shown in Fig. 5c, the TEER only de-
clined to <8 % of the starting value after incubation with
indicated doses of Cn and HIV-1 gp41-I90 or joint use of
them. These results suggest that Cn and gp41-I90 could in-
duce monocyte adhesion to and transmigration across the
HBMEC monolayers.
HIV-1 gp41-I90 and Cn synergistically enhance the adhesion
and transmigration activity of monocytes
In this assay, the adhesion rate of THP-1 was measured in
four groups: PBS, Cn, HIV-1 gp41-I90 and joint use of Cn
and HIV-1 gp41-I90 (Fig. 3a). Compared with the control
group, all other groups showed significant increase in the
adhesion rates, among which the HIV-1 gp41-I90 + Cn
group was the highest. For the time-course study of THP-
1 transmigration, as shown in Fig. 3b, when the incubation
time was increased to 24 h, the transmigration rate of
HIV-1 gp41-I90 + Cn group increased to 32 % compared
to the Cn group (19.2 %) and HIV-1 gp41-I90 group
(21.8 %). Therefore, we concluded that the co-exposure of
HIV-1 gp41-I90 and Cn in HBMEC has a significant time
effect in transmigration of THP-1 cells. Moreover, the co-
exposure group showed a higher rate initially, and the
pro-migration effect was more durable as well. Determin-
ation of a synergistic effect of Cn and HIV-1 gp41-I90
combination was performed according to the median ef-
fect principle using the CalcuSyn Software (Biosoft) as de-
scribed previously [52]. The CI values for the combination
treatment of Cn and HIV-1 gp41-I90 were less than 1,
suggesting that the combination is highly synergistic.
These results suggested that HIV-1 gp41-I90 and Cn was
able to synergistically enhance the adhesion and transmi-
gration activity of monocytes.
Specificity of synergistically enhanced transmigration
activity of monocyte by Cn and HIV-1 gp41
In Fig. 2, we showed evidence of a dose- and time-
dependent increase in monocyte transmigration activity
following BMEC treatment with Cn and HIV-1 gp41.
Fig. 1 Cn and HIV-1 gp41-I90 induce THP-1 adhesion to HBMEC monolayers in a dose- and time-dependent manner. THP-1 adhesion assays were
performed as described in the Methods section. a, c Induction of THP-1 adhesion with different doses (106-2 × 107 CFU/ml) of Cn and HIV-1 gp41
(0–20 μM). b, d Time-course study of Cn and HIV-1 gp41-I90-induced THP-1 adhesion to HBMEC monolayers. THP-1 adhesion was triggered by 5 ×
106 CFU/ml of Cn or 2 μM HIV-1 gp41-I90. Adhesion was expressed as an n-fold increase relative to the basal level. *P < 0.05, **P <0.01, ***P < 0.001
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However, it is not clear whether these enhancing effects
are specific to Cn and gp41. In order to further investigate
this issue, heat-inactivated Cn, HIV Tat and p24 were used
in transmigration assays. Briefly, HBMECs cultured in
trans-well filters were treated with either PBS (control),
Cn (1 × 106 CFU/ml), H-Cn (1 × 106 CFU/ml), HIV-1
gp41 (0.2 μM), HIV Tat (0.2 μM) or HIV p24 (0.2 μM) for
6 h. THP-1 transmigration assays were performed as
described as Methods section. Like Cn and HIV-1 gp41,
as shown in Fig. 4a, H-Cn and HIV Tat could also increase
monocytes transmigration across BBB. Among these
stimulations, the HIV Tat molecule contributes a higher
enhancement of monocytes transmigration across to BBB.
Next, we performed transmigration assays again to further
examine whether H-Cn and HIV-1 gp41 or Cn and HIV
Tat could also synergistically enhance the transmigration
Fig. 2 Cn and HIV-1 gp41-I90 induce THP-1 transmigration across HBMEC monolayers in a dose- and time-dependent manner. a, c Different doses
(106-2 × 107 CFU/ml) of Cn and HIV-1 gp41-I90 (0–20 μM) induced THP-1 transmigration. b, d Time-course study of Cn and HIV-1 gp41-I90-induced
THP-1 transmigration across HBMEC monolayers. THP-1 transmigration was triggered by 5 × 106 CFU/ml of Cn or 2 μM HIV-1 gp41-I90. The values
represent the mean percent transmigrating THP-1 of triplicate samples and are representative of one experiment from three independent experiments
showing similar data. *P < 0.05, **P <0.01, ***P < 0.001 compared with control
Fig. 3 Cn and HIV-1 gp41-I90 co-induced adhesion and transmigration of THP-1 to HBMEC. a Induction of THP-1 adhesion with Cn and HIV-1
gp41 alone or Cn in combination with HIV-1 gp41. The adhesion of THP-1 was triggered by 5 × 106 CFU/ml of Cn, 2 μM of HIV-1 gp41-I90 or
both of them. Joint use of Cn and HIV-1 gp41-I90 significantly induced THP-1 adhesion at 1.5 h after addition of THP-1 to the monolayer when
compared with use Cn and HIV-1 gp41 alone. b Time-course study of Cn and HIV-1 gp41-I90 induced THP-1 transmigration across HBMEC
monolayers. THP-1 transmigration was triggered by 5 × 106 CFU/ml Cn, 2 μM HIV-1 gp41-I90 or both of them. The values represent the mean
of triplicate samples and are representative of one experiment from three independent experiments showing similar data. (*P < 0.05, **P < 0.01)
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activity of monocyte. However, as shown in Fig. 4a–c,
none of them could synergistically enhance the transmi-
gration activity of monocyte. The synergistic effect was de-
termined using the CalcuSyn Software as described above.
The enhancement of Cn and HIV-1 gp41-I90 in transmigration
of monocytes across the BBB is closely related to CD44
The HIV-1 envelope glycoprotein gp41 could up-regulate
CD44 in AIDS patients with CM, which ultimately en-
hances the adhesion and invasion of Cn to BMECs [18, 53].
In order to examine whether Cn and HIV-1 gp41-I90
enhance the transmigration of monocytes across the BBB is
mediated by CD44, two different blockage approaches,
genetic knockdown (KD-CD44 HBMEC) and chemical
inhibition (CD44 inhibitor Bikunin) were used. KD-CD44
HBMEC was generated by the CRISPR Cas 9 genome edit-
ing technique, which is an effective way to down-regulate
expression of protein in a broad variety of mammalian cells
[54, 55]. The down-regulating effect of Cas9 was measured
at the protein level by Western blotting, approximately
77 % knock-down was achieved (Fig. 5a, b). In order to en-
sure that the barrier remains intact in the absence of CD44,
the integrity of the barrier of KD-CD44 HBMEC was evalu-
ated by TEER. As shown in Fig. 5c, stimulation of Cn and
HIV-1 gp41-I90 alone or together has no significant
effect on integrity of the barrier. Furthermore, we also
performed Western blotting to examine the effect of
down-regulated CD44 expression on tight junction pro-
tein ZO-1. As shown in Fig. 5d, the absence of CD44
has no effect on ZO-1 expression in HBMEC. THP-1
transmigration assays were performed with HBMEC,
SC (scramble control) HBMEC and KD-CD44 HBMEC
as described as Method section. As shown in Fig. 5e,
significant reduction of THP-1 transmigration was
observed in the KD-CD44 HBMEC groups.
Bikunin is a serine protease inhibitor, which was con-
firmed to have an inhibitory effect on CD44 [56, 57]. As
shown in Fig. 5f, when the dosage of Bikunin was raised to
1 nM, it showed a significant inhibition on the enhance-
ment of monocytes transmigration rate in Cn infected-
HBMEC. Comparing to the control group (17.4 %), the
monocytes transmigration rates of Bikunin group was
down to 11 and 7.8 %, respectively with dosage 5 nM and
20 nM (Fig. 5f). Similar, Bikunin could also remarkably
block enhancement of HIV-1 gp41-I90 in transmigration
of monocytes across BBB. Hence, we concluded that,
HIV-1 gp41-I90 and Cn enhance the monocyte transmi-
gration across BBB is mediated by CD44.
Fig. 4 Specificity of Cn and HIV gp41 in induced monocyte transmigration across HBMEC monolayers. a Monocytes transmigration rate of Cn,
H-Cn, HIV-1 gp41, HIV Tat, and HIV p24. HBMEC monolayers were treated with Cn, H-Cn, gp41, Tat or p24 respectively. Transmigration assays we
performed as described as Methods section. b These are no synergistic effect of monocytes transmigration following BMEC treatment with H-Cn
and HIV-1 gp41. c These are no synergistic effect of monocytes transmigration following BMEC treatment with Cn and HIV Tat. The values represent
the mean percent transmigrating THP-1 of triplicate samples and are representative of one experiment from three independent experiments showing
similar data. *P < 0.05, ***P < 0.001 compared with control
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HIV-1 gp41-I90 and Cn induce up-regulation of CD44 and
ICAM-1 on HBMEC
After demonstrating the effect of Cn and HIV-1 gp41 in
monocytes transmigration across BBB in vitro, we focused
on the role of Cn and HIV-1 gp41 in up-regulation of
endothelial adhesion molecules that might be involved in
monocytes transmigration. Surface expression of endothe-
lial adhesion molecules was studied by using two ap-
proaches, western blotting and whole-cell BA-ELISA. As
shown in Fig. 6a, b, following 6 h exposure of HBMEC to
Cn and HIV-1 gp41-I90, significantly increase in surface
expression of ICAM-1 and CD44 was observed. The data
of BA-ELISAs were similar to Western blotting, as shown
in Fig. 6d, e, the highest expression level of ICAM-1 and
CD44 were observed in HBMEC treated with Cn in com-
bination with HIV-1 gp41-I90. Interestingly, as shown in
Fig. 6c, expression of CD44 in KD-CD44 HBMEC was
up-regulated significantly following co-exposure to Cn
and HIV-1 gp41-I90, although there was a slight increase
in CD44 upon treatment of Cn or HIV-1 gp41-I90 alone.
The threshold of induced monocytes transmigration and
up-regulated CD44 expression by HIV-1 gp41
In the process of studying the effect of HIV-1 gp41-I90
on the transmigration of monocytes across the BBB in
vitro, we were able to observe there is a limitation in
the induced monocytes transmigration across BBB by
HIV-1 gp41-I90. As shown in Fig. 7a, there was very
little increase in transmigration rate 26.24 to 26.81 %,
when the concentration of HIV-1 gp41-I90 was in-
creased from 20 to 25 μM. This indicates a saturation
level of monocytes transmigration, when the HIV-1
gp41-I90 concentration is approaching 25 μM. We fur-
ther performed a BA-ELISA to confirm the biological
relevance of this finding. HBMECs were treated with
different dose of HIV-1 gp41-I90 (from 2 to 25 μM),
the whole-cell BA-ELISA were performed as described
Methods section to assess the expression of CD44 on
the surface of HBMEC. As we expected, there is also a
limitation of CD44 expression when the concentration
of HIV-1 gp41-I90 was increased from 20 to 25 μM
(Fig. 7b). Taken together, the results clearly demonstrate
that there is a threshold in the enhancement of monocytes
transmigration and over-expression of CD44 induced by
HIV-1 gp41-190.
Redistribution of CD44 to membrane rafts of HBMEC
during Cn and HIV-1 gp41-I90 exposure
Adhesion molecules recruited to specialized microdo-
mains of lipid rafts is important to regulate intracellular
signaling and leukocyte transendothelial migration [58].
Thus, we tested whether Cn and/or gp41-190 could
induce CD44 redistribution to the membrane lipid rafts
of HBMEC. As CD44 could be a membrane receptor on
HBMEC, we used density gradient centrifugation to frac-
tionate membrane rafts. HBMECs treated by Cn and/or
Fig. 5 Genetic (Knock-down) and chemical (inhibitor) blockage of CD44 results in a reduction of THP-1 transmigration across HBMEC. a, b
Down-regulating effect of the CRISPR Cas9 system was measured by Western blotting. β-actin was used as a loading control for each sample.
Results showed a significant decrease (77 %) in the CD44/β-actin optical density ratio (***P <0.001). c Effect of Cn and HIV-1 gp41 on the BBB
permeability, as evaluated by TEER. HBMEC, SC HBMEC or KD-CD44 HBMEC cultures were treated with Cn (2 × 107 CFU/ml), HIV-1 gp41 (20 μm) alone
or Cn in combination with HIV-1 gp41 for 6 h. Either Cn or HIV-1 gp41 alone or joint use of them had no significant effect on the permeability of
HBMEC, SC HBMEC and KD-CD44. d Effect of down-regulated CD44 expression on ZO-1 in HBMEC. e Transmigration assays were performed with
HBMEC, SC HBMEC and KD-CD44, a significant suppression of transmigration was observed in the KD-CD44 group. f Bikunin inhibits Cn- and HIV-1
gp41-I90- induced THP-1 transmigration across HBMEC in a dose-dependent manner. An uninfected BMEC as a negative control was designed in the
assay. Results are expressed as the mean and standard deviation of quadruplicate assays. (*P < 0.05, **P <0.01, ***P < 0.001)
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HIV-1 gp-41 were lysed in a buffer containing 1 % Triton
X-100. The fractionation was performed in OptiPrepTM
density gradient centrifugation. After centrifugation,
detergent-insoluble membrane lipid raft fractions floated to
the interphase between 0 % and 20 % OptiPrepTM layers,
peaking at fraction 2 in our study (asterisk in Fig. 8). The
loading buffer floated to the top (fraction 1), but soluble
proteins or cytoskeleton associated, detergent-insoluble
proteins remained in the bottom fractions of the gradient
(fractions 3–9). Protein blotting of each fraction was used
to examine the distribution of protein components from
HBMEC extracts of the Cn and/or gp41-treated samples.
As shown in Fig. 8, in untreated HBMEC, CD44 was pri-
marily associated with soluble fractions (fractions 6–9). For
the cells treated with either Cn and/or HIV-1 gp41-I90, a
significant portion of CD44 had apparently relocated to the
membrane rafts as observed in the fraction 2. The result
suggested that there was a reorganization of membrane
rafts taking place during exposure to Cn and/or HIV-1
gp41-I90, and CD44 became enriched in these membrane
rafts on the surface of HBMEC, which facilitates the mono-
cytes transmigrate across the BBB.
Fig. 6 Cn and HIV-1 gp41 enhanced expression of CD44 and ICAM-1 on the HBMEC. Western blotting analyses were performed to measure the
up-regulating effect of CD44 (a, c) and ICAM-1 (b) on HBMEC or KD-CD44 HBMEC following exposure to Cn and/or HIV-1 gp41. The β-actin was
used as a loading control for each sample. Results showed a significant increase in the CD44/β-actin optical density ratio (P < 0.01compared with
control). Expression of ICAM-1 (d) and CD44 (e) was analyzed by BA-ELISAs. Assays were performed in triplicates. Results were expressed as an
n-fold increase of protein expression, taking the control as 1. The significant differences between the treatment and control were marked with
asterisks (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 7 There is a limitation in the induced transmigration of monocytes and up-regulated expression of CD44 by HIV-1 gp41-190. HBMEC were
treated with different dose of HIV-1 gp41-I90 (2–25 μM) for 6 h. Transmigration assays (a) and BA-ELISAs (b) were performed to assess whether
transmigration of monocytes and expression of CD44 induced by HIV-1 gp41-190 is dose-dependent. The values represent the mean percent
transmigrating THP-1 of triplicate samples and are representative of one experiment from three independent experiments showing similar data.
(*P < 0.05, **P <0.01, ***P < 0.001)
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HIV-1 gp41-I90 increased Cn-induced monocyte
transmigration, the BBB permeability and injury in vivo
To further validate the biological relevance of the in vitro
assays, the role of HIV-1 gp41-I90 in the monocyte trans-
migration across the BBB induced by Cn was tested in the
mouse model, as described in Methods section. Animals
of the same age were injected with Cn (106 cells) or HIV-1
gp41-I90 (10 μg/g mouse weight) alone or Cn in combin-
ation with HIV-1 gp41-I90. Three indexes, monocytes
transmigration, EB concentration in brain tissue and num-
ber of cBMEC in blood were used to evaluate the pathoge-
nicities of CM. As shown in Fig. 9a–c, all above indexes
shown highest mean in the mice injected with Cn in com-
bination with HIV-1 gp41-I90. These results show that
HIV-1 gp41-I90 and Cn could synergistically facilitate the
monocyte transmigration, increase the BBB permeability
(increased EB concentration in brain) and injury (in-
creased cBMEC in blood).
Since most monocytes are recruited into brain paren-
chyma adjacent to blood vessels during the cryptococcal
meningitis, next, we examined the effect of Cn and/or
HIV-1 gp41-I90 on recruitment of monocytes into the
brain parenchyma of mice. C57BL/6 mice were intraven-
ously injected with Cn and/or HIV-1 gp41-I90 via the tail
vein. After 24 h injection, mice were anaesthetized with
ketamine and lidocaine, and the brains were removed and
fixed in 4 % neutralbuffered formalin. Immunohistochem-
istry analysis was performed as described as Methods
section. As shown in Fig. 10, expose to Cn and/or HIV-1
gp41-I90 was able to significantly increase monocytes
transmigration across the BBB. These data suggested that
Fig. 8 Redistribution of CD44 to membrane rafts during HBMEC
exposure to Cn and/or HIV-1 gp41-190. HBMECs were treated with either
PBS or Cn, or HIV gp41-I90 or both of them for 6 h. The cells were then
lysed in buffer containing 1 % Triton X-100 on ice. Fractionation was
performed in OptiPrepTM gradients, and nine fractions were collected.
The lipid raft fractions are indicated by * in fraction 2. An equal volume
of each sample was analysed by dot blots using antibodies against
CD44. Redistribution of CD44 on the membrane rafts was observed in
Cn and/or HIV-1 gp41-I90 treated HBMECs
Fig. 9 Effects of HIV-1 gp41-I90 on Cn-increased monocyte transmigration, the BBB permeability and injury. a CSF concentration of monocytes in
mice treated with 106 CFU/ml Cn, 10 μg/g HIV-1 gp41-I90 or both of them. b Concentration of EB in brain of mice treated with 106 CFU/ml Cn,
10 μg/g HIV-1 gp41-I90 or both of them. c Peripheral blood concentration of cBMEC in mice treated with 106 CFU/ml Cn, 10 μg/g HIV-1 gp41-I90
or both of them. Mice were divided into 4 groups (6 mice/group). Each experiment was performed three times. *P < 0.05, **P < 0.01, ***P < 0.001
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expose to HIV-1 gp41-I90 increased Cn-induced mono-
cytes recruitment into CNS.
Discussion
Cn is an opportunistic pathogen, which causes fatal menin-
goencephalitis, especially in AIDS patients. In order to
cause meningoencephalitis, Cn must cross the BBB. A
great deal of evidence supports the existence of the Trojan
horse model of BBB transmigration of Cn. (1) Cn can sur-
vive in phagocytic cells via active phagosomal extrusion
and spread to the phagocytes [59, 60]; (2) The incidence
rate of fungemia and meningoencephalitis is higher in
HIV-1-infected patients than that in HIV-1-negative pa-
tients because HIV-1 can cause severe monocyte dysfunc-
tion in host [61–63]; (3) Cn was carried and transported by
circulating phagocytes in the murine model of cryptococ-
cosis in a previous study by Chrétien F. et al. [64]. (4) Cn is
a facultative intracellular pathogen and has been shown to
survive and multiply inside phagocytes in vitro [65]. Previ-
ous research had shown that HIV-1 infection is able to in-
crease the monocyte capacity to migrate across the BBB
[36]. In present study, we have suggested that Cn and/or
HIV-1 gp41-I90 is able to enhance the transmigration ac-
tivities of monocytes across BBB by using the in vitro and
in vivo BBB models [66]. Importantly, we found that HIV-
1 gp41-I90 was able to synergistically enhance the transmi-
gration activity of monocytes in HBMEC infected with Cn
and in mice with Cn-caused meningoencephalitis. Thus,
we have firstly demonstrated the relationship between
HIV-1, Cn and monocytes, which point out a new potential
mechanism of invasion for this pathogenic fungus into the
brain tissues of HIV-1-infected patients.
Initially, we demonstrated that the transmigration of
monocytes across the BBB in vitro could besynergistically
enhanced by HIV-1 gp41 protein and Cn. The specificity
of the synergistic effect is further confirmed by transmigra-
tion assays. Two experiments were designed. In the first
experiment, we used H-Cn to examine whether H-Cn and
HIV-1 gp41 could synergistically enhance the transmigrate
ability of monocytes. Our results have shown that there is
no synergistic effect on the transmigration of monocytes
with a combination of H-Cn and gp41. Interestingly, we
found that H-Cn could also increase monocyte transmigra-
tion ability. In the second experiment, HIV Tat and p24
proteins were used. HIV Tat is a regulatory protein that en-
hances viral transcription and replication, which plays a
multifaceted role in pathogenesis of HIV infection, includ-
ing favouring viral infection, contributing to inflammatory
responses and inducing monocyte invasion into the brain
[67–70]. Notwithstanding, we found there is no synergistic
effect on enhancement of monocyte transmigration upon
treatment by a combination of Cn and HIV-1 Tat protein.
Similarly, HIV p24, which is a component of the HIV par-
ticle capsid, also has no synergistic effect on Cn-mediated
Fig. 10 Recruitment of monocytes into the brain parenchyma of mice treated with Cn and/or HIV-1 gp41-I90. C57BL/6 mice were intravenously
injected with Cn and/or HIV-1 gp41-I90 via the tail vein. After 24 h injection, mice were anaesthetized with ketamine and lidocaine, and the brains
were removed and fixed in 4 % neutral buffered formalin. Immunohistochemistry analysis was performed as described as Methods section. a
Normal brain. b Brian of mice infected with Cn. c Brian of mice treated with HIV-1 gp41-I90. d Brian of mice treated with Cn + HIV-1 gp41-I90.
Arrows indicate infiltrating monocytes. Images are 400 ×
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enhancement of monocyte transmigration. Taken together,
these results suggest that the synergistic enhancement by
the HIV-1 gp41 protein on monocyte transmigration
across the Cn-infected BBB is viral factor-dependent. This
is most likely due to the fact that both HIV-1 gp41 and Cn
may elicit a similar signal, such as up-regulating CD44 and
ICAM-1 expression (Fig. 6), activating membrane lipid
rafts (Fig. 8) and NF-κB [44], to facilitate the transmigra-
tion of monocytes. Thus, we speculate that the ectodomain
of HIV-1 gp41 may play a role as a trans-predilection
factor for cryptococcal CNS invasion, suggesting that the
HIV-1 fusion inhibitors targeting gp41, such as T20 and
C34, may be helpful in the prevention and treatment of
cryptococcal meningitis in HIV/AIDS patients.
CD44 is a well-known type I transmembrane glycopro-
tein and functions as the major hyaluronan receptor,
which is widely distributed in a variety of endothelial
cells, mesenchymal cells, hematopoietic stem cells and
mesodermal cells and tissues. Although, alternative spli-
cing can produce a large number of different isoforms,
they all retain the hyaluronan-binding link-homology
region and a common transmembrane and cytoplasmic
domain [19]. Recent studies have demonstrated that, the
gene that encodes capsule hyaluronic acid synthase is a
key virulence gene of Cn. The transmigration process of
Cn across the BBB rely on HA binding to the BMEC
receptor CD44, which activates the host signal pathway
to induce cytoskeleton rearrangement required for Cn
invasion [71, 72]. In present study, we used the CRISPR-
Cas9 system and CD44 inhibitor to examine whether the
enhancement of Cn and HIV-1 gp41-I90 in transmigra-
tion of monocytes across the BBB is related to CD44.
Indeed, our results revealed that CD44 was involved in
the enhancement of monocyte transmigration across the
BBB by Cn and HIV-1 gp41.
Beside the effect of inducing monocyte transmigration
across the BBB in vitro, in present study, we also found
that Cn and/or HIV-1 gp41 could enhance CD44 redistri-
bution to the membrane lipid rafts and up-regulate the ex-
pression level of ICAM-1 and CD44, which are two major
endothelial adhesion molecules long known for its import-
ance in facilitating leukocyte transmigration. These find-
ings indicate that Cn and HIV-1 gp41-induced migration
of monocytes across BMEC in a coordinate manner with
up-regulation of ICAM-1 and CD44. Hence, we derived
the conclusion that, HBMEC co-exposed with Cn and
HIV-1 gp41 exhibited re-distribution of CD44 and
over-expression of CD44 and ICAM-1, which lead to
enhancement of the adhesion and transmigration rates
of monocytes and facilitate cerebral invasion of Cn.
During the process of studying the effect of HIV-1
gp41-I90 on the transmigration of monocytes across the
BBB, we found the facilitation of HIV-1 gp41-I90 induced
transmigration of monocytes is dose-dependent. When
the concentration of HIV-1 gp41 was raised to a certain
level, the facilitation get subdued, which remind us that,
there is a threshold in the over-expression of CD44
induced by HIV-1 gp41-I90. In order to test the above
assumption, different doses of HIV-1 gp41 (2–25 μM) was
added to the HBMEC monolayers to observe the transmi-
gration activities of monocyte. These results showed that
the facilitation induced by HIV-1 gp41-I90 was signifi-
cantly saturated with the higher concentrations of the
recombinant protein (Fig. 7a). Furthermore, we performed
BA-ELISAs to examine whether the over-expression of
CD44 induced by HIV-1 gp41-190 is also dose-dependent.
As we expected, the expression level of CD44 on HBMEC
could became saturated when the concentration of HIV-1
gp41-I90 was increased from 20–25 μM (Fig. 7b). These
results have profound clinical significance in antiretroviral
therapies for HIV-associated Cryptococoal meningo-
encephalitis, as it suggests that adherence to antiretroviral
therapies may minimize the risk of Cryptococoal neuro-
logic disease.
Conclusions
In conclusion, HIV-1 gp41-I90 and Cn is able to pro-
mote the adhesion and transmigration activities of
monocyte, and the co-exposure of HIV-1 gp41-I90 and
Cn further accelerate the adhesion and transmigration
activities of monocyte. This may result in a deteriorating
cryptococcosis in the infected host. The details for how
the HIV-1 enhances cryptococcal invasion into the hu-
man brain remain unclear. However, our studies provide
the enlightenments to establish the exact mechanism of
inflammatory responses induced by the HIV-1 gp41-I90
ectodomain often co-morbid with Cn that lead to HIV-
1-associated CM, and provide a theoretical basis for new
ways to effectively combat opportunistic infections of
the central nervous system in AIDS patients.
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